Comment on - Is add–on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta–analysis.

The article titled "Is Add-On Bevacizumab Therapy to Temozolomide and Radiotherapy Associated with Clinical Utility for Newly Diagnosed Glioblastoma? A Systematic Review and Meta-Analysis" provides a comprehensive review of the clinical utility of adding Bevacizumab to the standard treatment regimen for glioblastoma. The authors conducted a systematic review and meta-analysis, analyzing existing data to evaluate the potential benefits of this treatment strategy. While the study is commendably thorough, there are areas that warrant attention, such as potential selection bias in the inclusion criteria and the need for a more detailed analysis of heterogeneity among the included studies. Future research should focus on incorporating a broader range of studies and addressing publication bias to enhance the reliability of the results. Additionally, long-term outcomes and quality of life implications should be considered in future studies. Overall, this article offers valuable insights that could influence clinical decision-making and treatment protocols for glioblastoma patients. [Extracted from the article]